Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ...

Amiloride is noninferior to spironolactone in lowering home systolic blood pressure over 12 weeks in patients with resistant hypertension. The finding is from the SPironolactone Versus Amiloride for ...

Lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor, can substantially lower blood pressure in patients with uncontrolled and treatment-resistant hypertension, according to ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO, ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Numbers in parentheses (%) indicate the percentage of patients with follow-up measurements. An ellipsis indicates that the information is unavailable. eGFR: Estimated ...

In a country where nearly 1 in 3 adults silently battles high blood pressure , the need for regular blood pressure monitoring has never been more urgent. It's not just about early detection what ...